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http://dx.doi.org/10.1016/j.jds.2012.1Abstract Background/purpose: Periodontitis is related to diabetes mellitus. However,
whether periodontal therapy can affect glycemic control remains unclear. This study aims to
evaluate the effects of scaling and root planing (SRP) as well as enhanced root planing (ERP)
on the glycemic control and periodontal condition of patients with type 2 diabetes mellitus
(T2DM) and chronic periodontitis.
Materials and methods: Patients with T2DM and chronic periodontitis were randomly assigned
to treatment (nZ 49) and control (nZ 22) groups. The treatment group was treated with SRP,
whereas the control group remained untreated. After 3 months, the patients in the treatment
group were randomly divided into sub-ERP (nZ 25) and subprophylaxis (nZ 24) groups, which
were treated with ERP and prophylaxis, respectively.
Results: Hemoglobin A1c and fast plasma glucose levels in the treatment group decreased af-
ter SRP treatment. The changes in the hemoglobin A1c level in this group was significantly
greater than that in the control group (P < 0.05). The periodontal condition significantly
improved in the treatment group compared with that in the control group (P < 0.01). The
decrease in periodontal pocket depth in the sub-ERP group was more significant than that inof Periodontology, School and Hospital of Stomatology, Wuhan University, Number 237, Luoyu Road,
79, China.
ahoo.cn (C. Li).
iation for Dental Sciences of the Republic of China. Published by Elsevier Taiwan LLC. All rights reserved.
0.009
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Conclusion: This study suggests that SRP can be of benefit for the improvement of glycemic
control and periodontal condition. In addition, ERP can further improve the periodontal con-
dition of patients with T2DM.
Copyright ª 2013, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.Introduction
Glycemic control is a perennially important issue for people
with diabetes mellitus. A number of acute (hyperglycemic
hyperosmolar state, hypoglycemia, and ketoacidosis) and
chronic (cardiovascular disease, nephropathy, retinopathy,
neuropathy, etc.) complications are caused by prolonged
hyperglycemia; some of the complications may even lead to
death.1 The United Kingdom Prospective Diabetes Study in
the United States demonstrated that well-controlled hy-
perglycemia in type 2 diabetes mellitus (T2DM) can reduce
the risk of long-term diabetes mellitus complications.2
Periodontitis, a common public health issue, has been
considered a complication of T2DM.3,4 It is an inflammatory
disease that leads to periodontal tissue destruction.5 Peri-
odontal tissue destruction is mediated by bacterial toxins
and inflammatory cytokines in response to bacterial flora
and their products.6 The total surface area of the inflamed
and ulcerated epithelium of the periodontal pocket in an
individual with periodontitis is at least equal to the surface
area of the palm of the hand.7 The bacteria and their toxin
may enter the blood from this ulcerated area and lead to
systemic inflammation, which plays a major role in insulin
sensitivity and glucose dynamics.
As part of nonsurgical periodontal therapy, scaling and
root planing (SRP) is the major and most important treat-
ment method for periodontitis. This technique includes
supragingival/subgingival SRP. A number of studies investi-
gated the effect of nonsurgical periodontal treatment on
patients with T2DM. Several research groups reported that
improvements in the periodontal condition can promote
glycemic control.8e13 In a previous study, O’Connell et al10
designed a 30-sample trial to treat T2DM patients with
SRP þ doxycycline or SRP þ placebo, which yielded 1.5%
(SRP þ doxycycline) and 0.9% (SRP þ placebo) reduction in
the HbA1c level. Rodrigues et al8 performed trials similar to
that conducted by O’Connell et al; however, they found
that HbA1c significantly improved only in the SRP alone
group. Grossi et al13 also observed improvements in HbA1c
after SRP administration with doxycycline. Yun et al12 ar-
ranged two groups that were treated with systemic
administration only or SRP plus doxycycline, respectively.
The results show that both groups exhibited a reduction in
the HbA1c level; however, no significant difference be-
tween the two groups was observed. Navarro-Sanchez et al9
and Faria-Almeida et al11 compared the effects of SRP on
T2DM and nondiabetic patients, and found that HbA1c
significantly decreased in the T2DM group. These studies
were not randomized controlled trials (or the HbA1c out-
comes were not analyzed between treatment and control
groups). In addition, the results of parts of the studies were
combined with the systemic administration of antibiotics.Several studies reported the HbA1c reduction trends but
without indicating any statistical significance. Stewart
et al14 designed a clinical study on 72 T2DM patients with
periodontitis and suggested that periodontal therapy may
be associated with improvements in glycemic control.
However, the results had insufficient statistical value.
Jones et al.15 reported a randomized trial on 165 veterans
with poorly controlled diabetes over 4 months. They noted
that periodontal therapy showed promise in improving the
glycemic control without statistical significance. Another
study reported that periodontal therapy showed no signifi-
cant effect on the medical diabetes data through a clinical
study that involved seven insulin-dependent diabetics and
13 noninsulin-dependent diabetics.16 Given the incompat-
ible results that can be created by the different study
conditions, such as different inclusion and exclusion
criteria as well as distinct interventions, this single-blind
randomized controlled study aims to determine the rela-
tionship between SRP and glycemic control under relatively
strict clinical and experimental conditions in a Chinese
population with a low-calorie diet.
Although some authors reported that repeated SRP has
no additional effect on periodontal pocket reduction and
attachment gain compared with a single initial instrumen-
tation,17 repeated root planing can reduce the number and
proportions of periodontopathogenic bacteria in subgingival
plaque.18 Sigusch et al19 described a treatment concept
called second enhanced root planing (ERP), which is an
additional therapy to the initial SRP, and proved that ERP
can yield better long-term treatment outcomes on aggres-
sive periodontitis. Whether ERP could bring better prog-
nosis to chronic periodontitis accomplished with T2DM
similar to aggressive periodontitis should be determined.
Moreover, an increased postoperative infection on diabetes
after surgery was observed. King et al20 reported the pos-
sibility of increased postoperative infection when the mean
24-hour postoperative glucose concentration exceeds
150 mg/dL (8.3 mmol/L) after noncardiac surgery. Thus,
clinicians are always in a dilemma to determine whether to
continue with surgery or maintained phase (prophylaxis
scaling is the typical procedure that removes plaque and
calculus deposit) after initial periodontal treatment.
Therefore, this study also determined whether ERP can
yield higher curative effect on periodontitis with T2DM.Materials and methods
Sample population
Recruitment of participants for this single-blind, random-
ized, controlled clinical trial was started in July 2010. The
274 H. Zhang et alentire trial was completed in May 2011. A total of 400 T2DM
patients from the Hubei Provincial Government Hospital
(Wuhan, Hubei, China) were examined. Of these patients,
75 were recruited according to the inclusion criteria, and
informed consents were obtained. A questionnaire was
used to obtain the general information of patients,
including gender, date of birth, smoking habits, alcohol
consumption, present glycemic control scheme, and date of
DM diagnosis. The clinical trial was approved by the ethics
committee (School and Hospital of Stomatology, Wuhan
University) with approval number 200712. The clinic regis-
tration number is ChiCTR-CCC-00000365.
All individuals who participated in this study had chronic
periodontitis and had been diagnosed to have T2DM for
more than 1 year. A diagnosis of T2DM should meet at least
one of the following criteria: (1) postprandial plasma
glucose 200 mg/dL (11.1 mmol/L); (2) fast plasma glucose
(FPG) 126 mg/dL (7.0 mmol/L); (3) 2-hour oral glucose
tolerance test 200 mg/dL (11.1 mmol/L). In addition,
patients should have the following attributes: (1) 35 to 80
years old; (2) with at least 16 natural teeth; (3) with at
least four teeth with probing pocket depth (PPD) 5 mm,
clinical attachment loss (CAL) 4 mm, and bleeding on
probing (BOP), distributed in two or more oral quadrants;
and (4) the HbA1c level within 3 months before recruitment
should at least be 5.5%. The following exclusion criteria
were adopted: (1) accompanied with other systemic im-
mune diseases; (2) administered with antibiotics, immu-
nomodulators, contraceptives, or any other form of
hormone within the past 3 months; (3) underwent modified
diabetes treatment strategy within 3 months; (4) had
periodontal treatment within the past 12 months; (5)
needed extraction or endodontic treatment; (6) smokes
more than four cigarettes per day; (6) pregnant or lactating
women. Patients were dropped from the study if these
conditions were met during the study course: (1) the dia-
betes treatment scheme was changed; (2) drugs were sys-
temically administered; (3) the patients could not revisit on
time; and (4) the participants were lost on follow-up.
Sample size calculation
A preliminary trial was conducted on 10 patients with
periodontitis and T2DM. Five patients received SRP,
whereas the remaining patients were untreated. The
change in the HbA1c level from the baseline value to
3 months after therapy was recorded. The sample size was
calculated using the PASS software (version 11; NCSS,
Kaysville, Utah, USA). The magnitude of the change in
HbA1c was 0.20%. Given the 80% statistical power, 20 pa-
tients in the control group and 40 patients in the treatment
group were required with a´ Z 0.05.
Study design and procedure
The recruited patients were instructed to maintain their
previous diet and exercise habits and to inform the authors
whenever their glucose control treatment was changed.
After baseline evaluation, patients were randomly assigned
into two groups at a sample ratio of 2:1. Thus, 50 and 25
patients were included in the treatment and control groups,respectively. Patients in the treatment group underwent oral
health instructions, supra-/subgingival scaling (Cavitron
Bobcat Pro, Dentsply, York, PA, USA), and manual curettage
(Hu-Friedy, Chicago, IL, USA), which were completed within
2 weeks after the baseline evaluation. They were then
recalled for evaluation of their periodontal and biochemical
parameters (Evaluation2) 3 months after treatment. After-
ward, the patients in the treatment group were randomly
divided into the sub-ERP and subprophylaxis groups. Patients
in the sub-ERP group again received full-month ultrasonic
scaling and manual root planing of the teeth with PPD
4 mm. Meanwhile, the subprophylaxis group received only
full-month ultrasonic scaling to remove calculus and plaque.
Three months after the second intervention, all parameters
were measured for the third time (Evaluation3). The control
group was not given any periodontal treatment except for
evaluations at the baseline as well as on the 3rd and 6th
months. The procedure used in this study is described in
Fig. 1. After completion of the entire study, all volunteers in
the control group received initial periodontal treatment in
accordance with the provisions of the informed consent
form. Assignment to different groups was made using pre-
prepared randomization in group A, B, or C. Participants with
A and B were assigned to the treatment group and then
respectively assigned to the sub-ERP and subprophylaxis
groups, whereas individuals with C were assigned to the
control group. Cardswith group identificationwere prepared
and placed in number-coded envelopes as defined by SPSS
(version 17.0; IBM, NewYork, NY, USA). The randomcodewas
retained until the last patient had completed the entire
study. The single blind method was used in this study as the
examiner was blind to the intervention for the patients.
Outcome measures
The primary outcome measure was the HbA1c level evalu-
ated thrice in treatment and control groups. The secondary
outcomes were the FPG level and periodontal parameters,
which were also evaluated. The changes in the periodontal
condition after ERP or prophylaxis were also determined.
All patients were subjected to a periodontal clinical
examination, which was performed in six sites per tooth
(excluding the third molar) by a trained calibrated exam-
iner. The plaque index,21 BOP, PPD, and distance from the
gingival margin to the cementoeenamel junction were
examined using a Williams periodontal probe. If the gingival
margin is located apically to the cementoeenamel junc-
tion, the distance from the gingival margin to the cemen-
toeenamel junction is recorded positively. Thus, the
clinical CAL can be calculated by adding PPD to this dis-
tance. The FPG and HbA1c levels were measured using an
automatic biochemical analyzer (Beckman DXC800, USA)
and an HbA1c analyzer (Drew Scientific DS5, England, UK) in
the Clinic Laboratory Department of Wuhan General Hos-
pital of Guangzhou Military (Wuhan, Hubei, China). All pa-
rameters were examined within 3 days before or later than
the predetermined time.
Examiner calibration
The whole-mouth CAL was recorded by a single examiner in
three chronic periodontitis patients, and this was repeated
Figure 1 Flow diagram of this study. (a) One patient was lost to follow-up because of a business trip. (b) One patient quit because
he could not revisit on time and another quit voluntarily. (c) One patient quit voluntarily.
Periodontal treatment on diabetes mellitus 27524 hours later. Then, the intraexaminer reproducibility for
CAL was measured, and K coefficient (1 mm) Z 0.87.Statistical analysis
Data were analyzed using SPSS (17.0). For BOP, the per-
centage of positive sites was obtained for each patient
before the mean  standard deviation of each group was
calculated. The mean and standard deviation of plaque
index, PPD CAL, FPG, and HbA1c for each group were also
calculated.
The baseline balance between groups was determined
using the independent-sample t-test or the Pearson O2
test. In each group, the differences between three evalu-
ations were analyzed using the paired-sample t-test. The
differences after the interventions between groups were
analyzed using the independent-sample t-test. Statistical
significance was determined at an a´ level of 0.05.
Although not part of the original protocol, the patients
in the treatment group were reclassified as follows: pa-
tients who exhibited reduced or unchanged/increased
HbA1c levels 3 and 6 months after treatment were classi-
fied as effective or ineffective, respectively. The median
and interquartile range of the baseline FPG and HbA1c
levels in the two groups were calculated and analyzed using
the ManneWhitney U-test to determine the relationship
between the baseline glycemic condition and the effect of
SRP on HbA1c.Results
Sample statistics
A total of 71 of the 75 recruited patients finished the study.
One patient in the treatment group was lost to follow-up
because he went on a business trip. Two patients in the
control group quit voluntarily, whereas another quit
because he could not revisit on time (Fig. 1). The missing
data of the patients who quit were checked. The results
show that the missing data are not related to the outcomes.
Thus, the missing patients were ignored in the analysis
because they were missing at random completely.
No relevant differences in the general data (age, gender,
DM duration, smoking, alcohol consumption, drugs pre-
scription, other systemic diseases, and family history of DM)
were found. In addition, no significant differences between
the baseline periodontal and glycemic parameters of the
treatment and control groups were observed (Table 1).Primary outcome
The HbA1c level in the treatment group decreased from
Baseline to Evaluation2 (7.68  1.22% vs. 7.54  1.13%,
P < 0.01) and to Evaluation 3 (7.68  1.22% vs.
7.51  1.31%, P < 0.05). Compared with the control group,
the change in the HbA1c level from Baseline to Evaluation2
Table 1 Characteristics of sample populations at baseline.
Characteristic Treatment group (n Z 49) Control group (n Z 22) P
Age (y) 60.4  9.77 62.7  10.7 0.377
Gender (male/female) 21/28 10/12 0.838
Duration of DM (y) 8.63  4.20 7.29  5.61 0.305
Hypoglycemic drug
Oral drug 40 15 0.210
Insulin 30 11 0.376
Family history of DM 13 8 0.401
Other systemic diseases
Hypertension 20 10 0.714
Hyperlipemia 17 9 0.615
Cardiocerebral vascular diseases 15 6 0.776
Smoking 12 6 0.803
Alcohol consumption 13 7 0.647
Periodontal indices
PI 1.78  0.60 1.73  0.49 0.724
BOP (%) 55.7  16.5 52.8  15.0 0.480
PPD (mm) 2.50  0.45 2.43  0.47 0.593
CAL (mm) 3.41  0.97 3.33  0.97 0.752
Glycemic parameters
FPG (mmol/L) 7.68  0.90 7.51  1.13 0.486
HbA1c (%) 7.68  1.22 7.38  1.30 0.360
Data set represented as mean  SD or numbers of samples. BOPZ bleeding on probing; CALZ clinical attachment loss; DMZ diabetes
mellitus; FPG Z fasting plasma glucose; HbA1c Z hemoglobin A1c; PI Z plaque index; PPD Z probing pocket depth.
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(0.13  0.34% vs. 0.03  0.22%, P < 0.05) (Fig. 2B).Secondary outcome
In the treatment group, the FPG level decreased from
Baseline to Evaluation2 (138  16 vs. 135  20 mg/dL,
P < 0.05) and to Evaluation3 (138  16 vs. 135  19 mg/dL,
P < 0.05). Compared with the control group, no statistical
difference was found in the change in FPG (P > 0.05)
(Fig. 2A).
All clinical periodontal parameters in the treatment
group significantly improved from Baseline to Evaluation2Figure 2 Glycemic parameters of the treatment and the control g
All values are presented as mean  SD. Inner-group differences w
ferences were determined using independent-sample t-test.and to Evaluation3 compared with those in the control
group (P < 0.01) (Fig. 3). A statistical difference was found
only in the change in the PPD level from Evaluation2 to
Evaluation3 between the sub-ERP and subprophylaxis
groups (0.03  0.13 vs. 0.03  0.08, P < 0.05) (Fig. 4).Baseline glycemic condition after reclassification in
terms of SRP effect
After being classified as Effective and Ineffective according
to the HbA1c level variations observed 3 months after the
first intervention, the patients showed significant higher
baseline FPG levels (median, 7.84; interquartile range,roups during Baseline evaluation, Evaluation2, and Evaluation3.
ere analyzed using paired-sample t-test, and intergroup dif-
Figure 3 Clinical periodontal indices in the treatment and control groups during Baseline evaluation, Evaluation2, and Evalua-
tion3. All values are presented as mean  SD. Statistical significance is not shown in the figure. Inner-group differences were
analyzed using paired-sample t-test, and intergroup differences were determined using independent-sample t-test.
Periodontal treatment on diabetes mellitus 2777.30e8.71) in the Effective class compared with those in
the Ineffective class (median, 7.40; interquartile range,
6.76e8.12; P < 0.05) (Fig. 5A). The baseline HbA1c level inFigure 4 Periodontal indices in the sub-ERP (enhanced root pla
ation3. All values are presented as mean  SD. Inner-group differe
differences were determined using independent-sample t-test.the Effective class was also higher (median, 7.80; inter-
quartile range, 7.00e8.70) than that in the Ineffective class
(median, 7.30; interquartile range, 6.52e7.95; P > 0.05),ning) and subprophylaxis groups during Evaluation2 and Evalu-
nces were analyzed using paired-sample t-test, and intergroup
Figure 5 Baseline glycemic parameters of patients categorized in terms of changes in the HbA1c levels. The box plot shows the
median, interquartile range, and min/max values. (A, B) Patients categorized with first scaling and root planing (SRP) effect. (C, D)
Patients categorized with first SRP effect. Effective: patients with reduced hemoglobin A1c (HbA1c) levels. Ineffective: patients
with increased or unchanged HbA1c levels. The differences between groups were analyzed using the nonparametric ManneWhitney
U test.
278 H. Zhang et albut did not reach statistical significance (Fig. 5B). When
classified according to the results obtained on the 6th
month, no clear difference in the baseline FPG and HbA1c
levels was found (Fig. 5C and D).Discussion
Whether SRP can improve diabetes mellitus remains
controversial. HbA1c is one of the most important markers
in T2DM patients and is used to evaluate the severity of
diabetes as well as the glucose control condition. Any
reduction in the HbA1c level is likely to reduce the risk of
complications. Each 1% reduction in the HbA1c level would
bring a relative risk reduction of 21% for any diabetes-
related endpoint, 21% for diabetes-related deaths, 14% for
myocardial infarction, and 37% for microvascular compli-
cations.22 In this study, the HbA1c level in the treatment
group showed 0.17% (0.17  0.08%, P Z 0.039) reduction
during the evaluation at 3 months and 0.18% (0.18  0.12%,
P Z 0.121) reduction at 3 and 6 months after treatment,
respectively, compared with those in the control group
(Fig. 2B). This finding suggests that SRP can reduce the
plasma glucose level of T2DM patients. Simpson et al23
performed a meta review and reported that the mean
percentage difference in HbA1c after scaling/root planing
and oral hygiene (antibiotic therapy) versus no treat-
ment/usual treatment after 3e4 months was 0.40%, a
value higher than that obtained in the present study. Aspart of the included studies characterized by an accom-
panying antibiotic administration,12,15 the results may not
only reflect the SRP effect alone. Notably, tetracycline and
its derivatives can directly act on insulin production; thus,
the reduction in the HbA1c level may be attributed to
antibiotic administration.24 These conditions suggest that
SRP helps improve glucose control. By contrast, the FPG
level is an inferior screening parameter because of the high
variability of the experimental conditions, such as the
carbohydrate content of the last meal as well as the energy
expenditure between the last meal and the measurement.
Consequently, FPG has been used in combination with
HbA1c in many interventional trials that involve either di-
etary measures or hypoglycemic drugs to evaluate the
glycemic control condition.25,26 Fig. 2 shows a significant
reduction in the FPG level of the treatment group after SRP,
thus confirming the SRP effect on glycemic control.
As previously noted, periodontal surgery may not be
appropriate for uncontrolled DM patients. In this study, the
effects of ERP in deep pocket sites on glycemic control
were also determined. In Fig. 4C, the probing depth
reduction was higher in the repeated SRP group than in the
prophylaxis group. That is, in diabetes, ERP can increase
the periodontal therapeutic effectiveness in patients with
remaining deep periodontal pockets after the initial
treatment.
To obtain more accurate results, the exclusion criteria
and management of the study were strictly controlled.
First, only T2DM patients were included; second, patients
Periodontal treatment on diabetes mellitus 279with hopeless teeth or endodontic lesion that would lead to
extraction or cause pain during the study, which would
further affect the fluctuations in the plasma glucose con-
centration, were excluded; third, antibiotic administration
was not used in this study. Given the generally stable HbA1c
level in patients who did not receive other interventions,
patients were assigned to the treatment group and the
control group at a sample ratio of 2:1 to increase the
sample size in the treatment group.
Another finding of the present study is that the different
sensitivity of HbA1c to SRP may be caused by the different
baseline glycemic condition. It was thought that the more
severe the diabetes, the higher of the risk for therapy
complications during periodontal therapy. In this study, no
complication that can be correlated with periodontal
therapy was found, although the highest HbA1c level
reached 11.3%. Patients who showed decreased HbA1c
levels 3 months after SRP treatment exhibited higher
baseline FPG and HbA1c levels than those who exhibited
unchanged or increased HbA1c levels. This result indicates
that poorly controlled diabetes may be more sensitive to
the short-term effect of SRP (within 3 months). Kardesler
et al27 reported higher HbA1c level reduction in poorly
controlled T2DM patients (HbA1c 7%) than in well-
controlled patients (HbA1c <7%) after a 3-month observa-
tion. However, 6 months later, no evident difference was
found between the baseline FPG and HbA1c levels. There-
fore, poorly controlled diabetes may react faster after SRP
than well-controlled diabetes. In addition, the long-term
effect may be similar. Given the small sample size in this
study, additional work should be performed to confirm
these results.
In conclusion, periodontitis patients with T2DM should
receive SRP after a thorough examination, which improves
the periodontal condition as well as glycemic control. ERP
can further reduce the pocket depth in T2DM patients.
Therefore, regular periodontal examination and SRP should
be considered for diabetes-related healthcare, and ERP
may be suitable for T2DM patients with deep periodontal
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